David Toung

David Toung Recent News

Botox Competiton Spurs Argus To Downgrade Allergan
Generic Drug Pricing Taking A Bite Out Of Cardinal Health's Margins
As Gilead's Outlook Dims, Argus Downgrades
Amgen Downgraded After Top Products See Sales Slip In Q3
Gilead Gets An Upgrade Amid 'Game-Changing' Kite Deal
Putting Failed Aetna Deal Behind It, Humana Is Refocused On Growth; Analyst Upgrades The Stock
Has Celgene Become Vulnerable To 'Revenue Concentration Risk'?
Anthem Non-Renewal Still A Huge Risk For Express Scripts
Bristol-Myers Oncology Growth Potential Remains High
The Fate Of Humana Rests In The Hands Of A Federal Judge
Trump's Election Could Clear The Way For The Aetna-Humana Merger
Allscripts Posts Its Sixth Straight Quarter Of New Order Growth
Johnson & Johnson's Robust Pipeline Supports Its Above-Average Valuation
Becton Dickinson Shares Favorably Valued As It Works To Boost Earnings
Extended Contracts Should Boost The Top-Line For AmerisourceBergen Corp
Allergan's New Products And Robust R&D Pipeline Support A Positive Long-Term View
Zimmer Biomet Is In Position To Ramp Up Revenue Growth
Generic Drug Price Deflation Is Weighing On McKesson Shares
With Solid Growth And Strong Pipeline, Argus Is Positive On Celgene's Long-Term Prospects
Argus Upgrades Boston Scientific, Sees Market Share Gains And Strong Growth Ahead
St. Jude's Abbott Merger On Track For Q4
Express Scripts Margins Could Face Downward Pressure From Less Prescription Growth
Argus Talks Humana-Aetna Deal Uncertainty, Raises EPS Estimates For Humana

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved